State Key Laboratory of Genetic Engineering, Human Phenome Institute, Fudan University, Shanghai, China.
School of Life Sciences, Fudan University, Shanghai, China.
Cancer. 2020 May 15;126(10):2267-2278. doi: 10.1002/cncr.32789. Epub 2020 Mar 23.
The incidence of primary liver cancer (PLC) continues to increase worldwide. The incidence trends and patterns of PLC associated with different age at diagnosis remain unknown.
We collected detailed information on PLC between 1990 and 2017 from Global Burden of Disease Study 2017. Estimated annual percentage changes in the PLC age-standardized incidence rate (ASR) diagnosed by age, sex, region, and etiology were calculated to quantify the temporal trends in PLC ASR.
Globally, the number of PLC cases for which the age at diagnosis was <30 years decreased from 17,381 in 1990 to 14,661 in 2017, whereas the number of PLC cases diagnosed at age 30 to 59 and ≥60 years old increased from 216,561 and 241,189 in 1990 to 359,770 and 578,344 in 2017, respectively. The ASR of PLC cases with age at diagnosis <30 years and between 30 and 59 years decreased in both sexes, whereas the ASR of PLC with age at diagnosis ≥60 years increased in males and remained stable in females at the global level. Males had a more dramatic increase in PLC diagnosed at age ≥60 years but a milder decrease in PLC diagnosed between 30 and 59 years of age. This decrease was attributed largely to the reduction in PLC caused by hepatitis B and hepatitis C and was consistent in most regions except for developed countries, in which the ASR of PLC increased irrespective of sex and age. The ASR of PLC due to nonalcoholic steatohepatitis (NASH) increased by the greatest magnitude in most regions.
PLC in highly endemic regions has been partly alleviated due to the potent control of hepatitis, especially among young and middle-aged people. However, an unfavorable trend was observed in most developed countries and in elderly populations. As such, PLC prevention schedules should give more attention to NASH and elderly patients.
原发性肝癌(PLC)的发病率在全球范围内持续上升。与不同诊断年龄相关的 PLC 发病趋势和模式尚不清楚。
我们从 2017 年全球疾病负担研究中收集了 1990 年至 2017 年期间 PLC 的详细信息。通过按年龄、性别、地区和病因计算 PLC 年龄标准化发病率(ASR)的年度百分比变化,以量化 PLC ASR 的时间趋势。
在全球范围内,诊断年龄<30 岁的 PLC 病例数从 1990 年的 17381 例减少到 2017 年的 14661 例,而诊断年龄在 30 岁至 59 岁和≥60 岁的 PLC 病例数从 1990 年的 216561 例和 241189 例增加到 2017 年的 359770 例和 578344 例。诊断年龄<30 岁和 30-59 岁的 PLC 病例的 ASR 均在两性中下降,而诊断年龄≥60 岁的 PLC 的 ASR 在男性中增加,在女性中保持稳定。男性诊断年龄≥60 岁的 PLC 发病率增长更为显著,而 30-59 岁之间的 PLC 发病率下降幅度较小。这主要归因于乙型肝炎和丙型肝炎导致的 PLC 减少,且除发达国家外,在大多数地区都有此趋势,因为在这些地区,无论性别和年龄如何,PLC 的 ASR 都在增加。大多数地区的非酒精性脂肪性肝炎(NASH)导致的 PLC 的 ASR 增加幅度最大。
在高流行地区,由于对肝炎的有效控制,部分缓解了 PLC,特别是在年轻和中年人群中。然而,在大多数发达国家和老年人群中观察到了不利的趋势。因此,PLC 预防计划应更加关注 NASH 和老年患者。